Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nordic drugs ab - dexibuprofen - filmdragerad tablett - 300 mg - dexibuprofen 300 mg aktiv substans - dexibuprofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nordic drugs ab - dexibuprofen - filmdragerad tablett - 400 mg - dexibuprofen 400 mg aktiv substans - dexibuprofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aurobindo pharma (malta) limited - amoxicillintrihydrat; kaliumklavulanat - filmdragerad tablett - 500 mg/125 mg - amoxicillintrihydrat 573,4 mg aktiv substans; kaliumklavulanat 149 mg aktiv substans - amoxicillin och enzymhämmare

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aurobindo pharma (malta) limited - amoxicillintrihydrat; kaliumklavulanat - filmdragerad tablett - 875 mg/125 mg - amoxicillintrihydrat 1003,44 mg aktiv substans; kaliumklavulanat 149 mg aktiv substans - amoxicillin och enzymhämmare

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - amoxicillintrihydrat; kaliumklavulanat - filmdragerad tablett - 500 mg/125 mg - amoxicillintrihydrat 573,4 mg aktiv substans; kaliumklavulanat 149 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/850 mg - natriumlaurilsulfat hjälpämne; sitagliptinhydrokloridmonohydrat 56,68 mg aktiv substans; metforminhydroklorid 850 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/1000 mg - natriumlaurilsulfat hjälpämne; metforminhydroklorid 1000 mg aktiv substans; sitagliptinhydrokloridmonohydrat 56,68 mg aktiv substans